<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920215</url>
  </required_header>
  <id_info>
    <org_study_id>OPP-002-01EXT</org_study_id>
    <nct_id>NCT03920215</nct_id>
  </id_info>
  <brief_title>Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease</brief_title>
  <official_title>Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET Study)-Long Term Safety Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oyster Point Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oyster Point Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this safety long-term follow-up study is to evaluate the safety of OC-01&#xD;
      Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study OPP-002-01 was a long-term follow-up study of those subjects who had previously&#xD;
      participated in the OPP-002 study. The OPP-002 study was a Phase 2, multicenter, randomized,&#xD;
      double-masked, placebo-controlled study designed to evaluate the safety and efficacy of OC-01&#xD;
      nasal spray in adult participants with DED.&#xD;
&#xD;
      The first scheduled visit occurred 6 months after the first treatment of OC-01 nasal&#xD;
      spray/placebo in the OPP-002 study. The second scheduled visit occurred 12 months after the&#xD;
      first treatment of OC-01 nasal spray/placebo in the OPP-002 study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2019</start_date>
  <completion_date type="Actual">October 12, 2019</completion_date>
  <primary_completion_date type="Actual">October 12, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study.</measure>
    <time_frame>12 months</time_frame>
    <description>presence of new or changes to adverse events in the observation period</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Long Term Follow up Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>OC-01 Low Dose, 0.12 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray, 0.12 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC-01 Mid Dose, 0.6 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray, 0.62 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OC-01 High Dose, 1.2 mg/mL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OC-01 (varenicline) nasal spray, 1.2 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle) nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle) nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OC-01 (varenicline) nasal spray</intervention_name>
    <description>Long-term follow-up study is to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study.</description>
    <arm_group_label>OC-01 High Dose, 1.2 mg/mL</arm_group_label>
    <arm_group_label>OC-01 Low Dose, 0.12 mg/mL</arm_group_label>
    <arm_group_label>OC-01 Mid Dose, 0.6 mg/mL</arm_group_label>
    <arm_group_label>Placebo (vehicle) nasal spray</arm_group_label>
    <other_name>varenicline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have been enrolled in the OPP-002 study&#xD;
&#xD;
          2. Have received at least one dose of the study drug/placebo in OPP-002 study&#xD;
&#xD;
          3. Completed the OPP-002 study to Visit 5&#xD;
&#xD;
          4. Have provided verbal and written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Have discontinued prior to Visit 5 in the OPP-002 study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andover</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <disposition_first_submitted>January 26, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>January 26, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 28, 2021</disposition_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 10, 2021</submitted>
    <returned>October 7, 2021</returned>
    <submitted>October 21, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

